Response to tolvaptan and its effect on prognosis in cirrhotic patients with ascites.

@article{Kogiso2017ResponseTT,
  title={Response to tolvaptan and its effect on prognosis in cirrhotic patients with ascites.},
  author={Tomomi Kogiso and Kuniko Yamamoto and Mutsuki Kobayashi and Yuichi Ikarashi and Kazuhisa Kodama and Makiko Taniai and Nobuyuki Torii and Etsuko Hashimoto and Katsutoshi Tokushige},
  journal={Hepatology research : the official journal of the Japan Society of Hepatology},
  year={2017},
  volume={47 9},
  pages={835-844}
}
AIM The vasopressin V2 receptor antagonist tolvaptan has been used for the treatment of cirrhotic patients with ascites; however, no predictor of efficacy and prognosis has been developed. We evaluated candidate predictors of response to tolvaptan treatment. METHODS This was a single-center retrospective study. Overall, 97 Japanese cirrhotic patients (60 men, median age 63 years), who were hospitalized for ascites treatment including oral tolvaptan coupled with conventional diuretics, were… CONTINUE READING